

# QNZ

**Catalog No: tcsc1515**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

545380-34-5

**Formula:**

$C_{22}H_{20}N_4O$

**Pathway:**

Apoptosis;NF-κB

**Target:**

TNF Receptor;NF-κB

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 37$  mg/mL (103.81 mM)

**Alternative Names:**

EVP4593

**Observed Molecular Weight:**

356.42


## Product Description

QNZ shows strong inhibitory effects on **NF-κB** transcriptional activation and **TNF-α** production with **IC<sub>50</sub>**s of 11 and 7 nM, respectively. EVP4593 is a neuroprotective inhibitor of **SOC** channel.

IC50 & Target: IC50: 7 nM (TNF-α), 11 nM (NF-κB)<sup>[1]</sup>

SOC Channel<sup>[2]</sup>

**In Vitro:** QNZ (Compound 11q) has a suppressing effect of the NF-κB mediated-inflammatory response. QNZ inhibits edema formation dose-dependently<sup>[1]</sup>. QNZ (EVP4593) reduces the number of lysosomes/autophagosomes and store-operated channel (SOC) currents in Huntington's disease (HD). Normalization of calcium transport within neurons in response to QNZ is expected to reduce pathology manifestation. A number of lysosomes/autophagosomes are evaluated in HD and WT neurons treated with QNZ using transmission electron microscopy (TEM). Incubation with QNZ reduces the number of lysosomes/autophagosomes in HD GABAergic medium spiny (GABA MS)-like neurons (GMSLNs) by almost two-fold (from  $0.41 \pm 0.04$  to  $0.23 \pm 0.04$ ; p[2]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!